Treatment outcomes
tumor, cancer or therapy-related death
DISEASE PROGRESSION, MINOR, SECOND PRIMARY MALIGNANCY, TUMOR
As outlined above, 18/20 patients were available for response/progression analysis, and 19/20 patients were available for survival analysis. At the time of analysis, 11 patients were alive, and 8 had expired. Of the 8 expired patients, 3 had evidence of disease progression, 1 succumbed to a second primary malignancy, and 4 had no evidence of cancer or therapy-related death. Median follow-up was 25.8 months (range 7.6–41 months), and median OS was not reached (Fig. We evaluated early treatment response to two cycles of atezolizumab (before initiation of SABR). Evaluation of ICI responses after SABR is not possible. Unconfirmed partial responses were observed in 3/18 patients (17%), and three additional patients had a minor response with tumor reduction <30% (Fig. 